Zimmer Biomet — Nov 5, 2025 release

Page 4 of 24   Financial Guidance The Company is maintaining reported revenue growth and adjusted 2 earnings per share guidance and narrowing full-year 2025 constant currency and organic constant currency 1 revenue growth guidance to reflect currency expectations: Projected Year Ending December 31, 2025     Previous Guidance Updated Guidance 2025 Reported Revenue Change 6.7% - 7.7% 6.7% - 7.7% Foreign Currency Exchange Impact 0.5% 0.5% - 1.0% 2025 Constant Currency Revenue Change 6.2% - 7.2% 6.2% - 6.7% 2025 Organic Constant Currency Revenue Change (1) 3.5% - 4.5% 3.5% - 4.0% Adjusted Diluted EPS (2) $8.10 - $8.30 $8.10 - $8.30   (1) Excludes the projected impact of the Paragon 28 acquisition. Reconciliation of this measure to the most directly comparable GAAP financial measure is included in this press release. (2) This measure is a non-GAAP financial measure for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts. See “Forward-Looking Non-GAAP Financial Measures” below, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that this forward-looking non-GAAP financial measure may be materially different from the corresponding GAAP financial measure. Conference Call The Company will conduct its third quarter investor conference call today, November 5, 2025, at 8:30 a.m. ET. The audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com . It will be archived for replay following the conference call. About the Company Zimmer Bi